1 |
B. J. Druker and N. B. Lydon, Lessons Learned from the Development of an Abl
Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia, J Clin Invest.,
105, 3 (2000)
|
2 |
R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M.
Huberman, D. Karp, ]. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi,
Determinants of Tumor Response and Survival with Erlotinib in Patients with
Non - Small-Cell Lung Cancer, J Clin Oneal., 22, 3238 (2004)
DOI
ScienceOn
|
3 |
C. Garbe, A. Hauschild, M. Volkenandt, D. Schadendorf, W. Stolz, U. Reinhold, R. D. Kortmann, C. Kettelhack, B. Frerich, U. Keilholz, R. Dummer, G. Sebastian,
W. Tilgen, G. Schuler, A. Mackensen, and R. Kaufmann, Evidence and
Interdisciplinary Consense-based C'xerman Guidelines: Diagnosis and Surveillance of Melanoma, Melanoma Res., 17, 393 (2007)
DOI
ScienceOn
|
4 |
A. C. Buzaid and C. M. Anderson, The Changing Prognosis of Melanoma, Curro Oneal. Rep., 2, 322 (2000)
DOI
ScienceOn
|
5 |
S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch,
Preclinical Overview of Sorafenib, a Multikinase Inhibitor that Targets Both
Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling, Mol. Cancer
Ther., 7, 3129 (2008)
DOI
ScienceOn
|
6 |
C. M. Anderson, A. C. Buzaid, and S. S. Legha, Systemic Treatments for
Advanced Cutaneous Melanoma, Oncology, 9, 1149 (1995)
|
7 |
D. H. Lawson, Choices in Adjuvant Therapy of Melanoma, Cancer Control,
12, 236 (2005)
PUBMED
|
8 |
L. Serrone, M. Zeuli, F. M. Sega, and F. Cognetti, Dacarbazine-based
Chemotherapy for Metastatic Melanoma: Thirty-year Experience Overview, J. Exp. Clin. Cancer Res., 19, 21 (2000)
PUBMED
|
9 |
S. A. Rosenburg, M. T. Lotze, J. c. Yang, P. M. Aebersold, W. M. Linehan,
C. A. Seipp, and D. E. White, Experience with the Use of High Dose Interleukin-2
in the Treatment of 652 Cancer Patients, Ann. Surg., 210, 474 (1989)
DOI
ScienceOn
|
10 |
L. V. Dubey and I. V. Dubey, Side Reactions of Onium Coupling Reagents
BOP and HBTU in the Synthesis of Silica Polymer Supports, Ukr. Bioorg.
Acta, 1, 13 (2005)
|
11 |
J. A. Carlson, J. S. Ross, A. Slominski, G. Linette, J. Mysliborski, J. Hill, and M.
Mihm, Jr., Molecular Diagnostics In Melanoma, J Am Arod Dermatol., 52, 743 (2005)
DOI
ScienceOn
|
12 |
W. S. Fletcher, D. S. Daniels, V. K. Sondak, B. Dana, R. Townsend, H. E.
Hynes, L. F. Hutchins, and ]. R. Pancoast, Evaluation of Cisplatin and
DTIC in Inoperable Stage III and IV Melanoma, Am J. Clin. Oncol., 16, 359
(1993)
DOI
ScienceOn
|
13 |
M. R. Middleton, J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, and N. Thatcher, Randomized Phase III Study of Temozolomide versus Dacarbazine in the Treatment of Patients with Advanced Metastatic Malignant Melanoma, J Clin Oneal., 18, 158 (2008)
|
14 |
M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J.
Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S.
A. Rosenberg, High-dose Recombinant Interleukin 2 Therapy for Patients with
Metastatic Melanoma: Analysis of 270 Patients Treated between 1985 and 1993,
J. Clin. Oncol., 17, 2105 (1999)
DOI
PUBMED
|
15 |
A. L. Ruchelman, J. E. Kenigan, T. - K. Li, N. Zhou, A. Liu, L. F. Liu, E. J.
LaVoie, Nitro and Amino Substitution within the A-ring of 5H-S,9- dimethoxy-5- (2-N ,N -dimethylaminoethyl) dibenzo[c,h] [l,6]naphthyridin -6-ones: Influence on Topoisomerase I-Targeting Activity and Cytotoxicity, Bioorg. Med Chem, 12, 3731 (2004)
DOI
ScienceOn
|
16 |
A. Y. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, U.
Trefzer, A. C. Pavlick, R. DeConti, E. M. Hersh, P. Hersey, J. M. Kirkwood, and F. G. Haluska, Bd-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group, J
Clin Oneal., 24, 4738 (2006)
DOI
ScienceOn
|
17 |
S. A. Laufer, D. M. Domeyer, T. R. F. Scior, W. Albrecht, D. R. ]. Hauser,
Synthesis and Biological Testing of Purine Derivatives as Potential
A TP-competitive Kinase Inhibitors, J. Med Chem, 48, 710 (2005)
DOI
ScienceOn
|
18 |
D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZDI839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic
Strategy in Non-small Cell Lung Cancer, Semin Oneal., 29 (Supplement 4), 37
(2002)
|